# Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

NCT05806164

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Phase 4 |
| **Sponsor** | Women and Infants Hospital of Rhode Island |
| **Enrollment** | 432 participants |

## Key Eligibility Criteria

### Inclusion (7)

- years or older
- report at least "quite a bit bothered" or worse by their UUI defined by response to OAB-q-SS item #8 "How bothered are you by urine loss associated with a strong desire to urinate?"
- are not and do not plan to become pregnant
- have persistent UUI defined as previous unsuccessful results after conservative and anticholinergic treatment, or are unable to tolerate or have contraindications to anticholinergics
- are currently not taking anticholinergics or are willing to stop medication for 3 weeks prior to enrollment.

... and 2 more (see full listing online)

### Exclusion (9)

- clinical contraindication to beta-3 agonist or onabotulinumtoxinA
- prior therapeutic trial of either study treatment
- unevaluated hematuria, current or prior bladder malignancy
- surgically altered detrusor muscle
- prior pelvic radiation

... and 4 more (see full listing online)

## Locations (5 total)

University of Alabama at Birmingham, Birmingham, Alabama, United States
University of California, San Diego, San Diego, California, United States
Howard University, Washington D.C., District of Columbia, United States
... and 2 more locations